期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 80, 期 10, 页码 1339-1344出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2021-220597
关键词
-
类别
资金
- NIH/NIAMS [R01AR074500, T32-AR-069515]
- NIH/NIAID [UM1AI148574]
- Rheumatology Research Foundation (Scientist Development Award)
- Bloomberg Philanthropies COVID-19 Initiative
- Pfizer COVID-19 Competitive Grant Programme
- Beatrice Snyder Foundation
- Riley Family Foundation
- National Psoriasis Foundation
- Deutsche Forschungsgemeinschaft (DFG) [FOR2886, CRC1181]
- Bundesministerium fur Bildung und Forschung (BMBF)
- Bayerisches Staatsministerium fur Wissenschaft und Kunst
- ERC Synergy grant 4D Nanoscope
- IMI
- Emerging Fields Initiative MIRACLE of the Friedrich-Alexander-Universitat Erlangen-Nurnberg
- Else Kroner-Memorial Scholarship [2019_EKMS.27]
The study found that patients with immune-mediated inflammatory diseases (IMIDs) on methotrexate treatment showed impaired humoral and cellular immune response to COVID-19 mRNA vaccines, while healthy subjects and IMID patients on biologic treatments demonstrated strong antibody responses. These results suggest that different strategies may need to be explored to enhance immunization efficacy for IMID patients on methotrexate treatment.
Objective To investigate the humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment. Methods Established patients at New York University Langone Health with IMID (n=51) receiving the BNT162b2 mRNA vaccination were assessed at baseline and after second immunisation. Healthy subjects served as controls (n=26). IgG antibody responses to the spike protein were analysed for humoral response. Cellular immune response to SARS-CoV-2 was further analysed using high-parameter spectral flow cytometry. A second independent, validation cohort of controls (n=182) and patients with IMID (n=31) from Erlangen, Germany, were also analysed for humoral immune response. Results Although healthy subjects (n=208) and patients with IMID on biologic treatments (mostly on tumour necrosis factor blockers, n=37) demonstrate robust antibody responses (over 90%), those patients with IMID on background methotrexate (n=45) achieve an adequate response in only 62.2% of cases. Similarly, patients with IMID on methotrexate do not demonstrate an increase in CD8+ T-cell activation after vaccination. Conclusions In two independent cohorts of patients with IMID, methotrexate, a widely used immunomodulator for the treatment of several IMIDs, adversely affected humoral and cellular immune response to COVID-19 mRNA vaccines. Although precise cut-offs for immunogenicity that correlate with vaccine efficacy are yet to be established, our findings suggest that different strategies may need to be explored in patients with IMID taking methotrexate to increase the chances of immunisation efficacy against SARS-CoV-2 as has been demonstrated for augmenting immunogenicity to other viral vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据